ALNYLAM PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 143.3 USD | -0.28% |
|
-0.76% | -25.13% |
| 04-08 | Sector Update: Health Care Stocks Flat to Higher Premarket Monday | MT |
| 04-08 | Sector Update: Health Care | MT |
Chart calendar Alnylam Pharmaceuticals, Inc.
4c9b49c4d57df82f8.8Ah6wDaP2a86HCXpjb-ixrgeToi8Hc9ZpwU6VMjdf3g.tWUSmmLVjepoeHCv__T78t9oIPr6ZYMs8ncMYr2YFRC_ZSmoWdyenFlMRg~67b43a104e236690a56ae781191a12e3
Upcoming events on Alnylam Pharmaceuticals, Inc.
Past events on Alnylam Pharmaceuticals, Inc.
| 08/04/2024 00:00 | KARDIA-2 Phase 2 Study Results Call |
| 25/03/2024 17:00 | Canaccord Genuity Genetic Medicine for Generalists Conference |
| 20/03/2024 14:00 | Stifel CNS Day |
| 12/03/2024 14:15 | Barclays Global Healthcare Conference |
| 05/03/2024 14:10 | TD Cowen Health Care Conference |
| 15/02/2024 13:30 | Q4 2023 Earnings Call |
| 15/02/2024 13:00 | Q4 2023 Earnings Release |
| 08/01/2024 17:45 | JPMorgan Healthcare Conference |
| 13/12/2023 13:30 | R&D Day |
| 29/11/2023 14:30 | Piper Sandler Healthcare Conference |
| 14/11/2023 14:45 | Stifel Healthcare Conference |
| 14/11/2023 10:00 | Jefferies London Healthcare Conference |
| 02/11/2023 12:30 | Q3 2023 Earnings Call |
| 02/11/2023 12:00 | Q3 2023 Earnings Release |
| 24/10/2023 | Clinical Trials on Alzheimers Disease Conference |
| 09/10/2023 13:30 | ONPATTRO FDA Approval Call |
| 08/10/2023 13:24 | Heart Failure Society of America Scientific Meeting - Poster 030 |
| 07/10/2023 22:21 | Heart Failure Society of America Scientific Meeting - Poster 021 |
| 07/10/2023 00:00 | Heart Failure Society of America Scientific Meeting - Poster 087 |
| 10/08/2023 15:30 | Canaccord Genuity Growth Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 220 221 -0.43% | 493 476 3.49% | 844 823 2.64% | 1 037 1 013 2.41% | 1 828 1 827 0.1% | 1 853 |
|
EBITDA Million USD | Released Forecast Spread | -885 -857 -3.28% | -794 -773 -2.74% | -661 -608 -8.65% | -741 -646 -14.71% | 0,00 -250 - | -363 |
|
EBIT Million USD | Released Forecast Spread | -939 -893 -5.24% | -828 -833 0.51% | -709 -665 -6.58% | -785 -813 3.38% | -282 -275 -2.6% | -414 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -885 -853 -3.84% | -856 -826 -3.59% | -852 -750 -13.68% | -1 127 -1 138 1% | -434 -437 0.72% | -500 |
|
Net income Million USD | Released Forecast Spread | -886 -860 -3.08% | -858 -832 -3.22% | -853 -758 -12.46% | -1 131 -1 156 2.16% | -440 -441 0.12% | -515 |
|
EPS USD | Released Forecast Spread | -8,11 -7,93 -2.21% | -7,46 -7,18 -3.86% | -7,20 -6,42 -12.12% | -9,30 -9,42 1.32% | -3,52 -3,53 0.29% | -4,10 |
| Announcement Date | 06/02/20 | 11/02/21 | 10/02/22 | 23/02/23 | 15/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 259 234 10.66% | 213 243 -12.17% | 225 256 -12.2% | 264 292 -9.38% | 335 312 7.23% | 319 313 2.16% | 319 351 -9.08% | 751 395 90.22% | 440 442 -0.58% | 427 | 463 | 464 | 487 | 505 |
|
EBITDA Million USD | Released Forecast Spread | -183 -138 -32.84% | -137 -200 31.43% | -182 -206 11.98% | -247 -118 -110.59% | -174 -185 5.58% | -136 -204 33.36% | -217 -135 -60.01% | 227 -134 269.42% | -143 | -123 | -110 | -75,4 | -52,6 | |
|
EBIT Million USD | Released Forecast Spread | -195 -158 -23.33% | -147 -211 30.37% | -192 -173 -11.02% | -258 -195 -32.42% | -189 -221 14.57% | -150 -180 16.95% | -230 -136 -69.1% | 214 -165 229.79% | -116 -114 -2.24% | -117 | -97,7 | -113 | -106 | -111 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -260 -181 -43.44% | -239 -234 -2.18% | -275 -206 -33.41% | -406 -224 -81.14% | -207 -266 22.17% | -172 -237 27.24% | -274 -162 -68.79% | 151 -206 173.12% | -138 -149 7.5% | -133 | -114 | -133 | -124 | -128 |
|
Net income Million USD | Released Forecast Spread | -258 -181 -42.6% | -240 -235 -2.25% | -277 -205 -35.27% | -406 -221 -84.03% | -207 -234 11.5% | -174 -217 19.87% | -276 -168 -64.42% | 148 -184 180.46% | -138 -157 12.18% | -144 | -127 | -140 | -121 | -129 |
|
EPS USD | Released Forecast Spread | -2,16 -1,54 -40.21% | -2,00 -1,90 -5.45% | -2,29 -1,64 -39.55% | -3,32 -1,81 -83.85% | -1,68 -1,93 12.92% | -1,40 -1,73 19.14% | -2,21 -1,42 -56.08% | 1,18 -1,47 180.25% | -1,10 -1,25 11.8% | -1,17 | -1,04 | -1,10 | -0,97 | -0,99 |
| Announcement Date | 10/02/22 | 28/04/22 | 28/07/22 | 27/10/22 | 23/02/23 | 04/05/23 | 03/08/23 | 02/11/23 | 15/02/24 | - | - | - | - | - |
More events
Past sector events for Alnylam Pharmaceuticals, Inc.
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- ALNY Stock
- Calendar Alnylam Pharmaceuticals, Inc.
